首页> 外文OA文献 >Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

【2h】

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

机译：NAL-IRI含5氟尿嘧啶（5-FU）和Leucovorin或Gemcitabine Plus顺铂在晚期胆道癌症中 - NiFe试验（Aio-YMO HEP-0315）开放标签，非比较，随机，多中心二期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
L. Perkhofer; A. W. Berger; A. K. Beutel; E. Gallmeier; S. Angermeier; L. Fischer von Weikersthal; T. O. Goetze; R. Muche; T. Seufferlein; T. J. Ettrich;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study [J] . L. Perkhofer, A. W. Berger, A. K. Beutel, BMC Cancer . 2019,第1期

机译：Nal-IRI与5-氟尿嘧啶（5-FU）和亚叶酸或吉西他滨加顺铂治疗晚期胆道癌-NIFE试验（AIO-YMO HEP-0315）是一项开放性，非对照，随机，多中心II期研究
2. Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial). [J] . Takuji Okusaka, Makoto Ueno, Tosiya Sato, Journal of hepato-biliary-pancreatic sciences . 2012,第4期

机译：胆道癌免疫治疗的可能性：我们如何证明疗效？介绍当前正在进行的I期和II期随机研究，以评估在吉西他滨和顺铂中添加Wilms肿瘤1肽疫苗治疗晚期胆道癌的有效性和安全性（WT-BT试验）。
3. Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial) [J] . Takuji Okusaka, Makoto Ueno, Tosiya Sato, Journal of Hepato-Biliary-Pancreatic Sciences . 2012,第4期

机译：胆道癌免疫治疗的可能性：我们如何证明疗效？介绍当前正在进行的I期和II期随机研究，以评估在吉西他滨和顺铂中添加Wilms肿瘤1肽疫苗治疗晚期胆道癌的有效性和安全性（WT-BT试验）
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label non-comparative randomized multicenter phase II study [O] . L. Perkhofer, A. W. Berger, A. K. Beutel, 2019

机译：Nal-IRI与5-氟尿嘧啶（5-FU）和亚叶酸或吉西他滨加顺铂治疗晚期胆道癌-NIFE试验（AIO-YMO HEP-0315）是一项开放性非对照随机多中心II期研究
7. S‐1 as Monotherapy or in Combination With Leucovorin as Second‐Line Treatment in Gemcitabine‐Refractory Advanced Pancreatic Cancer: A Randomized, Open‐Label, Multicenter, Phase II Study [O] . Feijiao Ge, Nong Xu, Yuxian Bai, 2014

机译：S-1作为单药治疗或与Leucovorin结合在吉西他滨 - 难治晚期胰腺癌中的二线治疗：随机，开放标签，多中心，II期研究

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

著录项

相似文献

相关主题

期刊订阅